Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.

Oncology reports - 1 Oct 2017

Wang Xiaohong, Fu Runjia, Hu Ying, Du Hong, Li Shuangxi, Li Ziyu, Liu Yiqiang, Li Qixiang, Zhang Lianhai, Ji Jiafu

Abstract excerpt

Cetuximab has been evaluated as a first-line treatment with conflicting results. The aim of the present study was to investigate the relationship between epidermal growth factor receptor (EGFR) status, and response and survival benefit following cetuximab treatment in gastric cancer (GC). Using 20 patient-derived GC xenograft (PDX) models, the mice (10 mice/model) were randomly assigned into two groups. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Gene Expression Regulation, Neoplastic

Share to In Situ Hybridization, Fluorescence

Share to Stomach Neoplasms

Share to Survival Analysis

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 28849161
DOI: 10.3892/or.2017.5907

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.PMID 28849161Read ↗

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.Semantic proximity Read ↗

Patient-Derived Gastric Carcinoma Xenograft Mouse Models Faithfully Represent Human Tumor Molecular DiversitySemantic proximity Read ↗

Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine.Semantic proximity Read ↗

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.Semantic proximity Read ↗

Cetuximab response in CRC patient-derived xenografts seems predicted by an expression based RAS pathway signature.Semantic proximity Read ↗

Model-based analysis of response and resistance factors of cetuximab treatment in gastric cancer cell linesSemantic proximity Read ↗

Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.Semantic proximity Read ↗

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

EGFR Overexpression and Sequence Analysis of KRAS, BRAF, and EGFR Mutation Hot Spots in Canine Intestinal Adenocarcinoma.Semantic proximity Read ↗

Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Semantic proximity Read ↗

Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.Semantic proximity Read ↗

EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.